Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
PDL-1 Targeting in Resectable Oesophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2020-05-11
- Target Recruit Count
- 40
- Registration Number
- NCT03087864
- Locations
- 🇳🇱
Academic Medical Center, Medical Oncology, Amsterdam, Netherlands
Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors
- Conditions
- Appendix AdenocarcinomaHuman Papillomavirus-Related Anal Squamous Cell CarcinomaHuman Papillomavirus-Related Cervical Squamous Cell CarcinomaHuman Papillomavirus-Related Squamous Cell Carcinoma of the PenisHuman Papillomavirus-Related Vulvar Squamous Cell CarcinomaNeuroendocrine CarcinomaPancreatic Neuroendocrine TumorRecurrent Merkel Cell CarcinomaRecurrent Nasopharynx CarcinomaRecurrent Peritoneal Malignant Mesothelioma
- Interventions
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 133
- Registration Number
- NCT03074513
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
- Conditions
- Interventions
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Gradalis, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03073525
- Locations
- 🇺🇸
Billings Clinic, Billings, Montana, United States
🇺🇸Prisma Health Cancer Institute, Greenville, South Carolina, United States
🇺🇸Dartmouth-Hitchcock Medical Center/ Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
- Conditions
- Interventions
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 69
- Registration Number
- NCT03063762
- Locations
- 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇫🇷Centre Léon Bérard - Centre régional de lutte contre le cancer Rhône-Alpes, Lyon, France
🇮🇹Universita di Modena e Reggio Emilia;Dipartimento di Oncologia ed Ematologia, Modena, Emilia-Romagna, Italy
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2021-02-10
- Target Recruit Count
- 73
- Registration Number
- NCT03059667
- Locations
- 🇫🇷
Mulhouse - CH, Mulhouse, France
🇫🇷Centre Antoine Lacassagne, Nice, France
🇫🇷Annemasse - CH, Ambilly, France
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 21
- Registration Number
- NCT03050060
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
- Conditions
- Interventions
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT03041311
- Locations
- 🇺🇸
Loma Linda University, Loma Linda, California, United States
🇺🇸Northside Hospital - Georgia Cancer Specialists, Atlanta, Georgia, United States
🇺🇦Lviv State Regional Treatment and Diagnostics Oncology Center, Lviv, Ukraine
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1301
- Registration Number
- NCT03038100
- Locations
- 🇺🇸
Columbus NCORP, Columbus, Ohio, United States
🇺🇸Ohio State University, Arthur James Cancer Hospital, Columbus, Ohio, United States
🇺🇸Greater Baltimore Medical Center, Baltimore, Maryland, United States
A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03029832
- Locations
- 🇺🇸
Arizona Oncology - HOPE Wilmot, Tucson, Arizona, United States
🇺🇸Nebraska Methodist Hospital; Cancer Center, Omaha, Nebraska, United States
🇺🇸University of Colorado, Denver, Colorado, United States
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 778
- Registration Number
- NCT03024996
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇨🇦Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada
🇨🇦Princess Margaret Cancer Center, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.